Skip to content

ADC Development: Targeted Treatment

The use of antibody-drug conjugates has become particularly prevalent in cancer therapy, although their development can be problematic in their execution. However, aptamers can be used as alternative affinity ligands to overcome these drawbacks. A piece in EBR, authored by the team at Aptamer Group discusses more.

Aptamers have an additional advantage as they are typically 5-10-fold smaller than antibodies, allowing greater tissue penetration
and cellular uptake.

Download Editorial    Aptamer Applications     Get in touch

Start your next project with Aptamer Group

Contact one of our experts today